Mitral valve repair is traditionally an open-heart surgery, performed through a large incision in the chest while a heart-lung bypass machine keeps blood circulating. But it doesn’t have to be. Today, many patients have their mitral valve repaired through minimally invasive approaches that use much smaller incisions, and some high-risk patients can avoid surgery entirely with a catheter-based procedure done through a blood vessel in the leg.
Which approach you’re offered depends on your anatomy, your overall health, and your surgeon’s expertise. Here’s what each option actually involves and how they compare.
The Traditional Open-Heart Approach
The conventional method uses a median sternotomy, a vertical cut down the center of the breastbone that opens the chest wide enough for the surgeon to see and reach the heart directly. Once the chest is open, a heart-lung bypass machine takes over. Blood is routed out of the body, oxygenated by the machine, and pumped back in, allowing the surgeon to stop the heart and work on the valve in a still, bloodless field. Bypass time for this approach averages around 111 minutes.
This is considered major surgery by any definition. It requires general anesthesia, a hospital stay of roughly one to two weeks depending on overall health, and a recovery period during which the breastbone heals. Full sternotomy remains the standard when patients have other conditions that rule out smaller incisions, such as a widened aorta (over 40 mm), significant calcium buildup in the aorta, severe peripheral vascular disease, or a history of right lung surgery that may have created scar tissue in the chest cavity.
Minimally Invasive Repair
Minimally invasive mitral valve repair achieves the same goal through a much smaller opening. Instead of splitting the breastbone, the surgeon makes a 4- to 6-centimeter incision along the ribs on one side of the chest. A small camera (endoscope) is inserted through the incision so the surgical team can see the valve on a screen. In robotic-assisted versions, tiny robotic instruments are inserted through one or more additional small incisions, and the surgeon controls them from a console.
This is still heart surgery. You’re still placed on a heart-lung bypass machine, and the heart is still temporarily stopped. But the smaller entry point means less trauma to the chest wall, less blood loss, and typically a faster return to normal activity. The trade-off is that the operation itself takes a bit longer. In matched comparisons, minimally invasive procedures averaged about 232 minutes of total surgical time versus 226 for sternotomy, with bypass time running about 146 minutes compared to 111. That extra time on bypass hasn’t translated into worse outcomes, and for many patients the recovery benefits outweigh it.
Not everyone qualifies. The same contraindications that protect patients from complications (aortic dilation, vascular disease, prior right chest surgery) apply here. Your surgeon evaluates your imaging and medical history to decide which route is safest.
Catheter-Based Repair Without Surgery
For patients who are too high-risk for any form of open-heart surgery, there’s a completely different option: transcatheter edge-to-edge repair, or TEER. This is not surgery in the traditional sense. A thin catheter is threaded through a vein in the groin up to the heart, where a small clip device is delivered to the mitral valve. The clip grasps the valve leaflets and pulls them together, reducing the leak without any chest incision at all.
TEER is less invasive but also less precise than surgical repair. It doesn’t fully reconstruct the valve the way a surgeon can during open repair, and it’s generally reserved for people whose surgical risk is too high due to age, frailty, or other serious medical conditions. Early complications like shortness of breath, irregular heart rhythms, and worsening heart failure have been linked more to open surgical approaches, which is one reason catheter-based repair exists as an alternative for vulnerable patients.
Surgical Risk and Success Rates
Mitral valve repair carries a mortality rate of about 1.16% overall, but for the majority of patients undergoing isolated repair for a leaky valve, the risk is under 1%. The median mortality risk is 0.55%, meaning most patients fall well below the average. Risk climbs if the surgeon needs to convert from repair to full valve replacement during the procedure, which happens in about 6% of cases. Patients who require that conversion face a mortality rate of roughly 3.2%, compared to just over 1% for those whose repair succeeds as planned.
The combined rate of death or any major complication (stroke, kidney problems, prolonged ventilation, deep infection) is about 8.9%. That number sounds higher, but it includes every complication of any severity across a broad patient population.
Long-Term Durability
One of the biggest advantages of repair over replacement is longevity. Ten-year survival rates for patients who have their valve repaired consistently outperform those who receive a replacement valve. Across multiple large studies, 10-year survival after repair ranges from about 69% to 87%, compared to 49% to 64% after replacement. These differences are statistically significant and hold up across different patient populations.
Reoperation rates are encouragingly low. About 89% to 94% of patients who have a repair are still free from needing a second operation at 10 years. That’s comparable to replacement valves, and in some studies slightly better. A systematic review of the long-term data concluded that mitral valve repair has durability equal to or better than replacement.
Recovery and What Comes After
Hospital stays after mitral valve repair average about 11 to 14 days, though minimally invasive patients often go home sooner than those who had a full sternotomy. The breastbone takes roughly 6 to 8 weeks to heal after sternotomy, during which you’ll have lifting restrictions and won’t be able to drive. Minimally invasive patients typically return to normal activities faster because the bone wasn’t cut.
After discharge, most patients are started on a blood thinner (usually warfarin) for about 30 days, with a target blood-thinning level of 2.5 INR. At the one-month follow-up, if your heart rhythm is normal, the blood thinner is stopped. Low-dose aspirin (81 mg) is continued indefinitely. This is a significant advantage over mechanical valve replacement, which requires lifelong blood thinners. The short anticoagulation period reflects how quickly the repaired tissue heals and re-covers itself with the body’s own lining cells, a process that generally completes within about three months.
How the Approach Is Chosen
Current guidelines from the American Heart Association and American College of Cardiology recommend that patients who meet the standard criteria for valve intervention have surgery (repair or replacement) performed when feasible. The choice between sternotomy, minimally invasive, or catheter-based repair depends on several overlapping factors: how severe the valve leak is, what’s causing it, the anatomy of your chest and blood vessels, your overall surgical risk, and the experience of your surgical team.
Centers that perform high volumes of mitral valve repair, like the Mayo Clinic (which has operated on more than 6,000 patients with degenerative mitral valve disease), tend to offer the full range of approaches including robotic-assisted repair. The surgeon’s experience with a particular technique matters as much as the technique itself. A skilled surgeon performing a sternotomy may produce better outcomes than an inexperienced one attempting a minimally invasive approach.
If you’re being evaluated for mitral valve repair, the most useful question isn’t whether it’s open-heart surgery. It’s which version of the procedure your surgical team recommends for your specific situation, and how many of those procedures they perform each year.